The Boston Ocular Surface Prosthesis as a novel drug delivery system for bevacizumab.
Corneal neovascularization causes deterioration of visual acuity and increases surface irregularities. Various techniques have been employed to help control the progression of corneal neovascularization; bevacizumab is a medication that targets the specific pathway of corneal neovascularization. The Boston Ocular Surface Prosthesis (BOSP) is a large diameter contact lens that aids in maintaining corneal surface integrity and may serve as a delivery system for topical bevacizumab. This paper reviews five patients who were treated with topical bevacizumab in their BOSP. All patients demonstrated improvement in their visual acuity and clinical exam. No adverse reactions were noted.
Lim
Mira
M
Ophthalmic Education, Massachusetts Eye and Ear Infirmary, 243 Charles St., Boston, MA 02114, USA. mira_lim@meei.harvard.edu
Jacobs
Deborah S
DS
Rosenthal
Perry
P
Carrasquillo
Karen G
KG
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001900:Boston; D003263:Contact Lenses, Hydrophilic; D003315:Cornea / Q000473:pathology / Q000503:physiopathology; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019736:Prostheses and Implants; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab